Introduction
Several viral vectors are being pursued as potential vehicles to express HIV antigens including CMV, measles, mumps, rubella, adenovirus, vaccinia, yellow fever, VSV and varicella . The live-attenuated rubella vaccine strain RA27/3 has a proven track record for safety and immunogenicity efficacy [27] [28] [29] with a single dose shown to induce humoral immunity and life-long protection against rubella infection. Rubella vaccine can also boost previously immunized persons, even in the presence of pre-existing rubella immunity [30] . The generation of rubella vectors carrying HIV genes has the potential to elicit durable immunity. The challenging task is the generation of viable recombinant rubella carrying immunogens of the required length. We previously demonstrated that rubella vaccine strain RA27/3 [31] can accommodate insertions up to ∼300 amino acids of SIV Gag at the structural insertion site located between the envelope E2 and E1 [18, 21] . Gene expression at this site is controlled by the strong subgenomic promoter, which assures efficient expression of the insert.
Using recombinant rubella vectors in macaques, we reported the induction of robust SIV/HIV-specific humoral responses [21] , which could be boosted upon re-exposure to the vector, indicating the [19] and details the vaccination timeline used for this Indian rhesus macaque study. Animals CL6A and CL6J had received RA27/3 rubella vaccine strains and sham DNA. Macaques CL67, CL49, CL6V had received rubella types 1 and 2 which were "no takes" and did not induce antibodies to rubella and also did not induce Gag-specific T cell immunity. The animals received sequential vaccinations with DNA and rubella vector type 3 or type 3*, referred to as rubella vector herein, expressing SIV Gag. The animals were analyzed for Gag-specific IFN-␥ T cell responses, and macaques positive for the MamuA*01 haplotype were also analyzed for Gag CM9 tetramer responses. development of memory B cells. Different prime-boost combinations including recombinant rubella vectors and DNA elicited even higher antibody responses with extended longevity (>9 months), indicating that the rubella-induced responses could be further augmented.
DNA as vaccine platform has several advantages related to its simplicity, scalability, and possibility of repeated applications due to lack of immunity against the vector (reviewed in [32] ). HIV/SIV DNA vaccines administered by the intramuscular route (IM) followed by in vivo electroporation (EP) were shown to induce high cellular and humoral immune responses that persisted for >5 years after the last vaccination [33] [34] [35] . The potency of these cellular immune responses was demonstrated by their ability to greatly reduce viremia in macaques infected with pathogenic SIV or SHIV, in both preventive and therapeutic vaccine studies [32] . Humoral responses could be significantly augmented by combining DNA vaccine with different boosts (protein, recombinant viral vectors) [32] .
In this report, we examined the Gag-specific cellular immune responses from macaques vaccinated with rubella vectors or with DNA and rubella vectors in different prime-boost combinations. We focused on Gag as antigen, because Gag-specific T cell responses were reported to correlate with control of viremia in infected individuals [36] [37] [38] [39] and such responses are expected to reduce viremia in both preventive and therapeutic vaccination protocols.
Methods

Cellular immune response analysis in vaccinated macaques
Macaques were sequentially vaccinated via the IM route [19] with rubella vectors expressing four T cell epitopes (GY9, TE15, CM9 and ME11; vector type 3) or p27 gag and part of p2 gag (amino acids 135-391 of Gag; vector type 3*) of SIVmac239 Gag [19] and SIV gag DNAs [40] .
Gag-specific cellular immune responses were measured at the day of vaccination and indicated time points thereafter using a Gag peptide pool [33] and Gag 181-189 CM9 tetramer [41] in MamuA*01 + macaques as detailed in Supplementary methods.
Results
Sequential vaccination regimens using recombinant rubella vectors and DNA
We tested the ability of recombinant rubella vectors to induce Gag-specific cellular immune responses in macaques. Fig. 1 shows the vaccination regimens, which included rubella vectors and DNA expressing SIV gag in different prime-boost regimens. Rubella vector type 3 and type 3* differ by the size of the gag insert, comprising 4 epitopes located in the p19 gag and p27 gag regions (type 3) or the complete p27 gag and p2 gag (type 3*), and both elicited antibodies against Rubella and SIV Gag in vaccinated macaques [19] . Some of the macaques were recycled from a previous study where they received the rubella vaccine strain RA27/3 (rubella vaccine) or rubella vectors types 1 and 2 which did not replicate in vivo or show a vaccine "take" and did not develop humoral [19] or cellular immunity to Gag (not shown).
This report focuses on the induction and characterization of cellular immune responses addressing the following questions: (i) Can rubella vector vaccination induce de novo Gag-specific cellular immune responses (5 animals: CL6A, CL6J, DCVV, CL67, CL49)? (ii) Can DNA vaccination boost pre-existing rubella vector induced responses (3 animals: CL67, CL49, DCVV)? (iii) Can rubella vector vaccination boost pre-existing DNA induced responses (7 animals: CL67, CL49, DCVV, CL6V, J6L, V584, V200)? (iv) Can a 2nd rubella vector vaccination boost responses after rubella vector priming (all 9 animals: CL6A, CL6J, CL67, CL49, DCVV, CL6V, J6L, V584, V200)?
Vaccination with rubella vectors induces Gag-specific T cell responses in macaques
Two macaques (CL6A, CL6J), previously vaccinated with the live-attenuated rubella vaccine strain RA27/3, were immunized one year later, when the anti-rubella antibody titer had slightly declined, with the rubella vector expressing SIV Gag. A single vaccination with rubella vector was able to induce Gag-specific cellular responses in both macaques, reaching up to ∼0.2% IFN-␥ + T cells ( Fig. 2A) . In CL6A, the responses were mediated by similar levels of CD4 + and CD8 + T cells, while CL6J showed a primarily CD4 + T cell response. The MamuA*01 + CL6A also showed a robust CM9-specific response, reaching ∼2.9% of CD8 + T cells ( Fig. 2B , upper panels).
Three other macaques (DCVV, CL49, and CL67) that developed anti-Rubella and anti-Gag antibody responses after a single immunization with the rubella vector [19] , were also examined for Gag-specific IFN-␥ + cellular immune responses ( Fig. 2A ). DCVV developed Gag-specific T cells (0.13%); CL49 did not develop a Gagspecific T cell response upon peptide stimulation, but showed low levels (0.03%) of Gag CM9 + -specific T cells, while CL67 failed to show Gag-specific T cell immunity. The difference in responsiveness could reflect known animal-to-animal variation of outbred macaques as we observed in prior studies [33, 34, 40] . Together, these data show that a single vaccination with rubella vector induced Gag-specific T cell responses in 4 of the 5 animals tested (80% response rate). A single vaccination with rubella vector induced Gag-specific T cell responses comparable to those obtained upon a single gag DNA vaccination (1 mg dose) using the efficient EP delivery method with a mean response of 0.025% IFN-␥ + T cells (unpublished). These responses were also similar to those obtained upon IM delivery of the Vaxfectin ® adjuvanted DNA (1 mg dose) which, although low, contributed to control of viremia [42] .
gag DNA vaccination in rubella vector primed macaques
We examined the effect of gag DNA boost in three animals (CL49, CL67, DVCC) previously vaccinated with rubella vector (Fig. 3A ) . Upon rubella vector vaccination, all animals were positive for anti-Rubella and anti-Gag antibody responses [19] , and macaques DCVV and CL49 were also positive for Gag cellular responses (Fig. 3A, week 20 of study; data from Fig. 2 ). Upon a single DNA vaccination (week 25 of study), all three animals showed an increase of the Gagspecific T cells ranging from 0.02 to 0.5% of IFN-␥ + T cells (upper panels, week 27). Analysis of the MamuA*01 + CL49 also demonstrated an increase of the CM9 response to 0.7% of CD8 + T cells (lower panel). Pre-existing immunity to rubella did not prevent successful vaccination with gag DNA.
Rubella vector boost of DNA-primed macaques
We tested the ability of rubella vector to boost pre-existing immunity induced by gag DNA vaccination in four macaques (Fig. 3B ). The gag DNA vaccine induced robust responses ranging from 0.25 to 0.5% of IFN-␥ + T cells (J6L, V584, V200, upper panels; note CL6V, could only be evaluated for the tetramer responses), similar to our previous results with IM/EP vaccinated macaques [33, 34, 40] . The MamuA*01 + J6L, V584 and CL6V also developed robust tetramer responses reaching ∼2% to 5% of CD8 + T cells (lower panels). The DNA-primed animals received a rubella vector vaccination (week 25 for J6L, V584, V200; week 57 for CL6V), resulting in increased Gag-specific responses (∼2-fold; reaching ∼0.5% of T cells) as well as an increase of the CM9 responses (3-to 5-fold; reaching ∼4-12% CD8 + T cells). In all animals, the Gag-specific responses were higher after the rubella vector boost compared to the peak responses obtained upon DNA vaccination, indicating a benefit of DNA vaccine prime and rubella vector boost regimen.
Boosting of pre-existing rubella vector induced immunity by 2nd rubella vector vaccination
To examine whether the Gag-specific cellular responses in rubella vector-primed macaques could be boosted by a 2nd vector vaccination, we tested animals primed with rubella vector only ( Fig. 3C ) or with DNA/rubella prime boost regimens ( Fig. 3A and B ).
Two macaques (CL6A, CL6J) primed with rubella vector had detectable Gag-specific cellular immune responses 11 months later, when they received a 2nd rubella vector vaccine (Fig. 3C ). This boost led to an increase of the T cell responses in CL6A of both Gag-specific IFN-␥ + T cells (∼0.2%) and the CM9 + CD8 + T cell responses (3%), and had a lesser effect in CL6J. The DNA primedrubella vector boosted animals (J6L, V584, V200, CL6V; Fig. 3B ) were immunized with a 2nd dose of recombinant rubella vector after a rest period of 8 to 11 months [week 57 (J6L, V584, V200) or week 100 (CL6V) of study]. In all macaques, the Gag-specific responses increased reaching 0.1-0.2% of IFN-␥ + T cells (upper panels) and 1.5-7% of CM9 + CD8 + T cells (lower panels). Similarly, rubella vector and DNA-primed macaques (CL49, CL67, DCVV; Fig. 3A ) received a 2nd dose of recombinant rubella vector after a 17.5 months rest period (week 100 of study). Two (CL49, DCVV) of three animals showed an increase of the Gag-specific IFN-␥ + T cells (0.2 to 0.4%, week 102 of the study, upper panels), and CL49 showed an increase, reaching ∼4%, of CM9 + CD8 + T cells (lower panel, week 102 of the study).
Together, we found that repeated vaccination with rubella vector is feasible and that a 2nd dose of rubella vector resulted in a statistically significant increase of Gag immune response (N = 8, Fig. 3D ), including both the IFN-␥ T cell (left panel) and tetramer responses (right panel). Our data further showed that DNA-primed macaques benefitted from a rubella vector boost given after various rest times (7 weeks and 6.5 months Fig. 3B; 17 .5 months, Fig. 3A ). Rubella vector vaccination significantly boosted the Gag cellular immunity in DNA-primed macaques (Fig. 3E) for both the IFN-␥ T cell (left panel) and the tetramer responses (right panel). Thus, rubella vector boosts could be administered a long time after the DNA priming, leading to a rapid and significant increase of Gag-specific cellular immunity. Together, these data demonstrate that a prime boost vaccine regimen combining rubella vectors and DNA vaccine greatly enhances the T cell responses to antigens such as SIV Gag.
Durability
We also monitored the durability of cellular immunity induced by the rubella vector. All macaques showed persistence of the Gag T cell responses monitored for ∼4-14 months after the last rubella boost (Fig. 3A-C) . Fig. 3A shows responses detectable for at least 3.5 months after the last rubella vector vaccination (∼0.2% of Gagspecific IFN-␥ + T cells at week 114 of study; upper panel; ∼0.3% of CM9 + CD8 + T cells; lower panel). Fig. 3B shows responses detectable at 8-11 months after the rubella vector boost (∼0.04% to 0.2% of Gag-specific IFN-␥ + T cells at week 57 of study; upper panel; ∼0.6% to 1.1% of CM9 + CD8 + T cells; lower panel). Similarly, Gag T cell responses were found even 11 months after a single rubella vector vaccination, albeit at low levels (Fig. 3C ). Both Gag-specific IFN-␥ + T cell responses and tetramer responses showed persistence after the 2nd rubella vector vaccination. Two of the animals (J6L, V584) were examined at 14 months after the 2nd rubella vector boost and maintained ∼0.5% of CM9 + T cells (Fig. 3B ). Thus, rubella vector boost was potent in inducing durable responses. (Fig. 4B ). Macaques CL6A, CL6J and DCVV showed induction of CM-like and EM T cells producing IFN-␥, with more cells having a CM-like phenotype. Subsequent vaccinations with rubella vector (CL6A and CL6J), DNA only (CL67), or DNA followed by rubella vector (CCL49, and DCVV) showed a similar distribution of antigen-specific EM and CM T cells, except CL6A which preferentially accumulated Gag-specific effector cells upon boosting with the rubella vector. Similarly, we found that DNA priming vaccination (CL67, CL49, J6L, V584, V200) induced both CM-like and EM Gag-specific T cells, with a greater proportion of CM-like T cells. Subsequent vaccinations with rubella vectors (J6L, V584, V200) did not change the distribution of the antigen-specific memory T cells. Together, these data show that rubella vector vaccination was able to potently prime and boost Gag-specific T cells having CM-like and EM phenotypes.
Characterization of the rubella vector vaccine induced Gag-specific T cell responses
Analysis of the cytotoxic potential of the Gag-specific T cells (Fig. 5 ) after priming with rubella vector (CL6A, CL6J, CL49, CL67, DCVV) or with gag DNA (J6L, V854, V200) was performed 2 weeks post-immunization. After a single vaccination with rubella vector, three of the five macaques (CL6A, CL6J, DCVV) showed a subset of IFN-␥ + and GzmB + double-positive T cells, demonstrating the presence of cytotoxic Gag-specific T cells. This T cell subset was also found upon boosting with either rubella vector (CL6A, CL6J) or with gag DNA followed by rubella vector (CL49, CL67, DCVV). As previously reported [33, 34, 40, 43] , priming with DNA induced Gagspecific T cells with cytotoxic potential (macaques J6L, V584, V200). Monitoring the cellular responses upon subsequent heterologous boosting with rubella vectors confirmed that the antigen-specific cytotoxic T cell subsets were maintained. We also found the presence of TNF-␣ producing Gag-specific T cells and a subset of TNF-␣ + and GzmB + double-positive T cells after vaccination with vector type 3 (CL6A, DCVV) and after vaccination with vector type 3* (CL49, DCVV, J6L, V585, V200) (data not shown). Taken together, these data demonstrate that rubella vector vaccination induces strong Gag-specific responses with cytotoxic potential (GzmB + ).
Discussion
We examined the cellular immune responses induced upon vaccination with recombinant rubella vectors expressing regions of SIV Gag and found that these vectors induce robust antigen-specific responses (up to ∼0.2% Gag-specific IFN-␥ + T cells; ∼3% CM9 + CD8 + T cells). This vaccine modality was able to induce Gag-specific responses of a magnitude comparable to those obtained upon a single gag DNA vaccination using the efficient EP delivery method. Such levels are higher than those found using other viral vectors such as MVA, Adenovirus or VSV and which were found to greatly benefit from a DNA prime [5, 6, 11, [15] [16] [17] [22] [23] [24] [25] . The rubella vector induced a balanced Gag-specific T cells immune responses mediated by CD4 + and CD8 + T cells with effector and central memory-like phenotype. In addition, the antigen-specific IFN-␥ + T cells harbor granzyme B, indicating cytotoxic potential.
Sequential vaccination showed that the rubella vector could also significantly boost preexisting responses, often reaching peak levels even higher than those induced by DNA vaccine alone. Remarkably, although the rubella vector boosts were given after prolonged rest periods (∼12-18 months), the responses rapidly increased, supporting their potency. In spite of the presence of anti-rubella antibodies, a 2nd dose of rubella vectors was able to significantly boost T cell responses, regardless of the order of the primary immunization with rubella vector and DNA vaccines ( Fig. 3) . Similarly, prior exposure to the rubella vaccine strain RA27/3 did not prevent induction by the rubella vector boost of Gag-specific antibodies, as reported previously [19] , or Gag-specific T cell responses reaching up to 3% CM9 + CD8 + T cells (CL6A, Fig. 2 ). This is in overall agreement with another report [30] , which showed that rubella vaccine could boost pre-existing rubella immunity in previously immunized humans. Thus, priming and boosting of naïve subjects with rubella vectors containing vaccine inserts is a feasible application. Our data also show that once the vector has successfully primed a response, it can be used to boost the response, despite the presence of anti-Rubella antibodies.
Longevity of responses is another critical feature of any vaccine. The RV144 vaccine trial elicited immunity that waned over time, and the transient nature of the vaccine-induced immune responses is thought to be, at least partially, responsible for the limited vaccine efficacy [44] . Although we detected cellular responses induced by rubella vector alone after ∼1 year in some animals (Fig. 3C) , the responses had waned considerably. Thus, these responses did not show the robustness reported using a recombinant CMV vector [45] or SIV DNA vaccine [33, 34, 43, 46] . On the other hand, it has been a common finding that DNA delivered by different methods has the remarkable ability to induce persistent immune responses in non-human primates [34, 35, 46] . As observed for other viral vector vaccines (MVA, VSV, vaccinia, adenovirus), the combination of rubella vectors with DNA prime augmented Gag immunogencity. Future studies will test the efficacy of recombinant rubella vector alone or in combination with DNA, two vaccine platforms that are safe in humans.
The current rubella vectors can accommodate vaccine inserts up to ∼300 amino acids in length. Thus, rubella vectors could be used to express well-defined T cell epitopes, or chimeric molecules expressing a selection of the most conserved epitopes from different HIV clades ( [47, 48] and references therein). Inclusion of HIV Gag conserved elements in DNA-based immunogens provided a critical step to focus the immune responses to such epitopes by avoiding decoy epitopes, and provided an effective strategy to broaden responses in vaccinated macaques, while others showed that responses to a few epitopes led to effective control of viremia [49] . Alternatively, since Gag-specific T cells have been associated with control of viremia in HIV-1 infected people [36] [37] [38] [39] , recombinant rubella vectors may provide an additional method to induce such responses. Recombinant rubella vectors expressing Gag display key features of an effective vaccine such as the induction of robust T cell responses with effector memory and central memory-like phenotype and cytotoxic potential (this work), and the stimulation of humoral responses [19] . Additional studies are needed to assess the efficacy of the recombinant Rubella vector vaccines as preventive and therapeutic vaccines.
Live-attenuated rubella vaccine has a number of advantages as a vaccine platform for SIV and HIV: the vector's safety and potency have been established in millions of children, and the recombinant rubella vector presents the immunogen in the context of an ongoing infection. The immune response to the Gag insert in rubella vectors includes long-lasting cytotoxic T cells (this report) and antibody immunity [19] . A strong T cell response may target infected cells early, reducing peak viremia, and during the chronic phase of infection, resulting in lower viral set point. The overlapping host range (macaque, man) will allow us to test the protective efficacy of new rubella vectors in the macaque model.
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